Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

Migliorini, Filippo; Maffulli, Nicola; Spiezia, Filippo; Peretti, Giuseppe Maria; Tingart, Markus; Giorgino, Riccardo

doi:10.1186/s13018-021-02497-0

Journal of Orthopaedic Surgery and Research

Table 1 Generalities and patient baseline data of the included studies

From: Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

Author, year	Journal	Mean follow-up (months)	Mean calcium daily supplement (mg)	Mean vit D daily supplement (UI)	Treatment	Administration	Samples (n)	Mean age	Mean BMI (kg/m²)	Mean BMD spine (g/cm²)	Mean BMD hip (g/cm²)	Mean BMD femur neck (g/cm²)
Anastasilakis et al. 2015 [56]	Osteoporos Int	12	1000	800	Denosumab	IM	32	63	28.80	0.97
Anastasilakis et al. 2015 [56]	Osteoporos Int	12	1000	800	Zoledronate	IV	26	63	28.70	0.94
Black et al. 2006 [57]	J Am Med Ass	60	655		Alendronate	OS	329	73	25.70	0.90	0.73	0.62
			667		Alendronate	OS	333	73	25.90	0.89	0.73	0.61
			635		Placebo	OS	437	74	25.80	0.90	0.72	0.61
Black et al. 2015 [58]	J Bone Min Res	36	1000–1500	400–1200	Zoledronate	IV	95	78	24.60		0.69	0.58
Black et al. 2015 [58]	J Bone Min Res	36	1000–1500	400–1200	Placebo	IV	95	78	25.00		0.71	0.58
Brown et al. 2014 [9]	Osteoporos Int	12			Denosumab	SC	852	68
					Ibandronate	OS	851	67
					Risedronate	OS	851	67
Chesnut et al. 2004 [59]	J Bone Min Res	36	500	400	Ibandronate	OS	977	69	26.20
					Ibandronate	OS	977	69	26.20
					Placebo	OS	975	69	26.20
Chung et al. 2009 [10]	Calcif Tissue Int	6	500	125	Ibandronate/risedronate	OS	176	61	23.30
Chung et al. 2009 [10]	Calcif Tissue Int	6	500	125	Risedronate/ibandronate	OS	176	62	23.40
Cosman et al. 2011 [60]	J Bone Min Res	12	1000–1200	400–800	Zoledronate/teriparatide	IV/SC	137	65	25.30	0.74	0.71
					Zoledronate	IV	137	66	25.30	0.72	0.68
					Placebo/teriparatide	IV/SC	138	64	25.30	0.73	0.71
Cosman et al. 2016 [61]	New England J Med	12	500–1000	600–800	Romosozumab	SC	3589	71
		12	500–1000	600–800	Placebo	SC	3591	71
		24	500–1000	600–800	Denosumab	SC	3589	71
		24	500–1000	600–800	Denosumab	SC	3591	71
Gonnelli et al. 2014 [62]	Bone	12	841	400	Zoledronate	IV	30	66	26.10	0.82	0.79
Gonnelli et al. 2014 [62]	Bone	12	870		Ibandronate	IV	30	67	25.70	0.82	0.79
Greenspan et al. 2015 [63]	J Am Med Ass	24	807	163	Zoledronate	IV	89	85	28.20	0.93	0.68	0.61
Greenspan et al. 2015 [63]	J Am Med Ass	24	763	168	Placebo	IV	92	86	26.90	0.97	0.70	0.62
Grey et al. 2009 [64]	J Clin Endocrinol Metab	24	935		Zoledronate	IV	25	62		1.06	0.85
Grey et al. 2009 [64]	J Clin Endocrinol Metab	24	916		Placebo	IV	25	65		1.03	0.86
Grey et al. 2012 [65]	J Clin Endocrinol Metab	12	960		Zoledronate	IV	43	64		1.01	0.85
			880		Zoledronate	IV	43	66		1.03	0.84
			850		Zoledronate	IV	43	66		1.05	0.84
			950		Placebo	IV	43	65		1.03	0.87
Guanabens et al. 2013 [11]	Hepatology	24	1000		Ibandronate	OS	14	65	26.60	0.90	0.84	0.79
Guanabens et al. 2013 [11]	Hepatology	24	1000		Alendronate	OS	19	63	26.60	0.88	0.81	0.77
Hooper et al. 2005 [66]	Climacteric	24			Risedronate	1OS	128	53		1.08
					Risedronate	OS	129	53		1.08
					Placebo	OD	126	53		1.08
Kendler et al. 2019 [67]	Osteoporosis Int	12	>1000	>800	Romosozumab	SC	16	69
					Romosozumab	SC	19	68
					Romosozumab	SC	14
					Romosozumab	SC	12
Iwamoto et al. 2008 [68]	Yonsei Med J	12	800		Alendronate	OS	61	70	21.90	0.62
Iwamoto et al. 2008 [68]	Yonsei Med J	12	800		ECT	OS	61	69	21.70	0.65
Iwamoto et al. 2011 [69]	Osteoporosis Int	6	800		Alendronate	OS	97	78	22.00
Iwamoto et al. 2011 [69]	Osteoporosis Int	6	800		Raloxifene	IM	97	82	21.90
Leder et al. 2015 [13]	The Lancet	48			Teriparatide-denosumab	SC	27	66	25.50	0.82		0.64
					Denosumab-teriparatide	SC	27	65	23.80	0.86		0.64
					Combined-denosumab	SC	23	65	25.90	0.85		0.64
Leder et al. 2014 [70]	J Clin Endocrinol Metab	24			Teriparatide	SC	31	66	25.50	0.82		0.64
					Denosumab	SC	33	66	24.10	0.87		0.64
					Combined	SC	30	66	25.40	0.86		0.64
Liang et al. 2017 [71]	Orthop Surg	24			Zoledronate	IV	155	57	21.80	0.63	0.75
Liang et al. 2017 [71]	Orthop Surg	24			Placebo	IV	95	57	21.60	0.63	0.75
Lufkin et al. 1998 [72]	J Bone Min Res	12			Raloxifene	OS	48	67	24.80	0.75	0.64
					Raloxifene	OS	47	67	26.20	0.81	0.69
			750	400	Calcium/vit D	OS	48	68	25.30	0.77	0.67
McClung et al. 2014 [73]	New England J Med	12	1000	800	Romosozumab	SC	44	67
					Romosozumab	SC	46	67
					Romosozumab	SC	49	67
					Romosozumab	SC	52	67
					Romosozumab	SC	53	67
					Alendronate	OS	47	67
					Teriparatide	SC	46	67
					Placebo	SC	47	67
McClung et al. 2009 [74]	Obstet Gynecol	24	500–1200	400–800	Zoledronate	IV	181	60	26.50	0.86		0.69
					Zoledronate-placebo	IV	154	60	27.30	0.86		0.69
					Placebo	IV	188	61	27.20	0.86		0.69
McClung et al. 2018 [75]	J Bone Min Res	12	1000	800	Denosumab	SC	127	67
McClung et al. 2018 [75]	J Bone Min Res	12	1000	800	Placebo	SC	131	67
Meunier et al. 2004 [76]	New England J Med	36	1000	400–800	Strontium ranelate	OS	719	69	26.20	0.73	0.69	0.59
Meunier et al. 2004 [76]	New England J Med	36	1000	400–800	Placebo	OS	723	69	26.20	0.72	0.68	0.59
Meunier et al. 2009 [77]	Osteoporos Int	12	1000	400–800	Strontium ranelate	OS	221	72		0.85		0.66
					Strontium ranelate	OS	434	72		0.72		0.58
					Placebo	OS	225	72		0.86		0.64
Miller et al. 2016 [14]	J Clin Endocrinol Metab	12	1000	800	Denosumab	SC	321	69	24.30
Miller et al. 2016 [14]	J Clin Endocrinol Metab	12	1000	800	Zoledronate	IV	322	70	24.30
Morii et al. 2003 [78]	Osteoporos Int	13			Raloxifene	OS	90	65	21.50	0.66
					Raloxifene	OS	93	65	21.90	0.67
					Placebo	OS	97	64	22.00	0.64
Paggiosi et al. 2014 [79]	Osteoporos Int	24	1200	800	Alendronate	OS	57	68	25.90	0.79	0.75	0.64
					Ibandronate	OS	58	67	26.40	0.80	0.78	0.64
					Risedronate	OS	57	67	26.80	0.81	0.80	0.67
					Control		226	38	25.10	1.07	0.97	0.86
Papapoulos et al. 2012 [80]	J Bone Min Res	24			Denosumab	SC	2343	75
Papapoulos et al. 2012 [80]	J Bone Min Res	24			Denosumab	SC	2207	75
Recknor et al. 2013 [81]	Obstet Gynecol	12	500	800	Denosumab	SC	417	67	25.50
Recknor et al. 2013 [81]	Obstet Gynecol	12			Ibandronate	OS	416	66	25.10
Saag et al. 2017 [82]	New England J Med	24			Alendronate	OS	2047	74	25.40
Saag et al. 2017 [82]	New England J Med	24			Romosozumab-alendronate	SC-OS	2046	74	25.50
Sanad et al. 2011 [83]	Climacteric	12	1500	400	Raloxifene	OS	35	63	26.50	0.73	0.69	0.63
					Alendronate	OS	31	62	25.80	0.75	0.72	0.63
					Raloxifene/alendronate	OS	32	63	26.30	0.75	0.71	0.64
Tsai et al. 2013 [84]	Lancet	12			Teriparatide	SC	31	66	25.50	0.82	0.76	0.64
					Denosumab	SC	33	66	24.10	0.87	0.77	0.64
					Teriparatide/denosumab	SC	30	66	25.40	0.86	0.76	0.64
Tsai et al. 2019 [85]	Lancet	15			Teriparatide-denosumab	SC	35	66	23.00	0.83	0.74	0.65
Tsai et al. 2019 [85]	Lancet	15			Teriparatide-denosumab	SC	34	67	22.80	0.79	0.74	0.62

Back to article page

ISSN: 1749-799X

Contact us

Submission enquiries: journalsubmissions@springernature.com